Novocure Ltd. (NVCR) News

Novocure Ltd. (NVCR): $16.18

1.00 (+6.59%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add NVCR to Watchlist
Sign Up

Filter NVCR News Items

NVCR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVCR News Highlights

  • For NVCR, its 30 day story count is now at 2.
  • Over the past 19 days, the trend for NVCR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • ROOT are the most mentioned tickers in articles about NVCR.

Latest NVCR News From Around the Web

Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

ROOT, Switzerland, December 27, 2023--Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024. Mr. Doyle and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in one-on-one meetings with investors throughout the event.

Yahoo | December 27, 2023

7 Nasdaq Stocks Down 59% Set to Soar at Least 141%

Wall Street loves a good comeback story.

Rich Duprey on InvestorPlace | December 13, 2023

15 Best Falling Stocks To Buy Now

In this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falling Stocks To Buy Now. With 2023 coming […]

Yahoo | December 8, 2023

The Top and Bottom Stocks of 2023

Top performing stocks in 2023 included those in the technology sector, taking advantage of developments in AI. The bottom performers included NVCR, which was punished because of its ovarian cancer trials' failure to improve survival rates in patients.

Yahoo | December 4, 2023

Evercore ISI Is Pounding the Table on Rivian (RIVN) Stock With Outperform Rating

Rivian stock is getting a boost on Tuesday after analysts at Evercore ISI weighed in on RIVN shares with a reiterated outperform rating.

William White on InvestorPlace | November 28, 2023

FCEL Stock Alert: FuelCell Energy Announces AI Deal With IBM

FuelCell Energy stock is climbing higher on Tuesday as investors in FCEL celebrate the company signing a deal with IBM!

William White on InvestorPlace | November 28, 2023

Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts

Novocure layoffs are coming for 13% of the company's workers as it seeks to reduce its headcount by 200 people to reduce costs.

William White on InvestorPlace | November 28, 2023

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

ROOT, Switzerland, November 28, 2023--Novocure today announced a series of actions to strengthen and optimize business operations to support growth drivers and long-term value creation.

Yahoo | November 28, 2023

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

ROOT, Switzerland, November 21, 2023--Novocure announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.

Yahoo | November 21, 2023

NovoCure Limited (NASDAQ:NVCR) institutional owners may be pleased with recent gains after 85% loss over the past year

Key Insights Given the large stake in the stock by institutions, NovoCure's stock price might be vulnerable to their...

Yahoo | November 16, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!